Overview

Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a highly immunogenic member of the MAGE-A family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors.

Based on our ongoing preclinical evaluation, we believe our ADP-A2M10 TCR therapeutic candidate has the potential ability to bind target peptides from multiple cancer types. We have two ongoing clinical trials to evaluate the safety and anti- tumor activity of ADP- A2M10: one for certain patients with non-small cell lung cancer, and one for certain patients with bladder, melanoma and head and neck cancers.

Pipeline

SPEAR
T-cell
Target Indications Target dose (Cohort) 5 BN+
(expansion)
Registration
studies
100 M (1) 1 BN (2) 5 BN (3)
ADP-A2M10 MAGE-A10 Non-small cell lung cancer (NSCLC)
100 M (1) Phase complete
1 BN (2) Phase complete
5 BN (3) Phase complete
5 BN+ (expansion) Phase in progress
Registration studies Phase not started
Triple Tumor (Bladder, Melanoma, Head & Neck)
100 M (1) Phase complete
1 BN (2) Phase complete
5 BN (3) Phase complete
5 BN+ (expansion) Phase in progress
Registration studies Phase not started